Nothing Special   »   [go: up one dir, main page]

Keam - Google Patents

A phase II study of pembrolizumab and paclitaxel in refractory small cell lung cancer

Keam

View PDF
Document ID
14573235053308244510
Author
Keam P

External Links

Snippet

5) Have measurable disease based on RECIST 1.1 6) Be≥ 20 years of age on day of signing informed consent. 7) Have a performance status of 0 or 1 on the ECOG Performance Scale 8) Have provided tissue for biomarker analysis from an archival tissue sample or …
Continue reading at cdn.clinicaltrials.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Keam A phase II study of pembrolizumab and paclitaxel in refractory small cell lung cancer
Richart et al. Phase 2B single-site, open-label, nonrandomized study evaluating the efficacy of neoadjuvant MK-3475 for unresectable Stage III and unresectable Stage IV melanoma
Australia PROTOCOL HISTORY
Khan et al. Failure of the PD-1 blocking agent pembrolizumab to benefit a patient with renal squamous cell cancer
Russo Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (< 50%) _ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors)
CONFIDENTIAL et al. A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)
Sundahl et al. Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma
CONFIDENTIAL et al. A Phase III study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM)(KEYNOTE 183)
CONFIDENTIAL et al. A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+ 5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059).
Protocol et al. Protocol Title
Masuda Phase II study of nivolumab+ abemaciclib+ endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer
CONFIDENTIAL et al. A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Fang The use of perfusion MRI using ferumoxytol and small molecular weight gadolinium (Gd) agents to assess response to pembrolizumab in brain metastases and systemic lesions in NSCLC: A comparison of imaging modalities to address brain metastases, pseudoprogression and systemic lesion tumor flare (neuro-check pilot)
Leemans Short title NeoNivo EudraCT number 2018-002643-28 Version 9 Date 11-12-2019 Principal investigators C. Willemien Menke-van der Houven van Oordt, MD PhD
CONFIDENTIAL et al. Phase IB Study of Pembrolizumab (MK-3475) in Subjects with Select Advanced Solid Tumors
Durvalumab Research Title: Phase I (Safety Assessment) of Durvalumab (MEDI4736) with Focal Sensitizing Radiotherapy in Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Epithelial Carcinoma
CONFIDENTIAL et al. A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
Halmos A Feasibility and Biomarker Study to Evaluate Necitumumab in the Neoadjuvant Setting with Gemcitabine and Cisplatin in Surgically Resectable Squamous Lung Cancer Coordinating Center: Montefiore Medical Center, Albert Einstein College of Medicine
des Moulins PROTOCOL NUMBER: MEDI4736-DLBCL-001 DATE FINAL: 20 Jul 2016 Amendment 1 09 May 2017 Amendment 2 02 Jan 2018 Amendment 3 27 Feb 2018
CONFIDENTIAL et al. A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer
ANTI-PD A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTI-CENTER, PHASE III CLINICAL STUDY OF ANTI-PD-1 ANTIBODY SHR-1210 VS. INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL CANCER
CONFIDENTIAL et al. A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Sirard CLINICAL STUDY PROTOCOL Protocol DEK-DKK1-P204
Sabari et al. A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC PD-L1 EXPRESSION IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC)
CONFIDENTIAL et al. Phase Ib Study of MK-3475 in Subjects with Advanced Melanoma